Conditionnement : 100mg
Téléphone : +1 850 650 7790
Synonyms: Leucovorin, HSDB 6544
| Description | Folinic acid (Leucovorin) is a biofolate used in the treatment of methotrexate (MTX) toxicity reduction and as an adjuvant therapy for colon cancer. |
| In vitro | Methotrexate (MTX) alone induces a concentration-dependent increase in the percentage of micronucleated binucleated cells (MNBN) and abnormal cells (Abs). As the concentration of MTX increases, the nuclear division index (NDI) decreases. Similarly, the mitotic index (MI) also decreases at all tested concentrations of MTX. The addition of 50 μg/mL folinic acid significantly reduces the % MNBN (40-68%) and % Abs (36-77%). In the presence of 5 μg/mL folinic acid, inhibitory effects are observed as well (MNBN from 12% to 54%, Abs from 20% to 61%)[2]. |
| In vivo | Treatment with folinic acid (7.0 mg/kg; intraperitoneal injection; every other day; for 3 weeks) appears to reverse the growth inhibition induced by Methotrexate (MTX) administration in young male Balb/c mice. Long-term MTX administration is known to inhibit skeletal growth in mice[1]. |
| Synonyms | Leucovorin, HSDB 6544 |
| Molecular Weight | 473.44 |
| Formula | C20H23N7O7 |
| Cas No. | 58-05-9 |
| Smiles | Nc1nc2NCC(CNc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)N(C=O)c2c(=O)[nH]1 |
| Relative Density. | 1.4485 g/cm3 (Estimated) |
| Storage | Keep away from direct sunlight,The compound is unstable in solution. Please use soon Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 260 mg/mL (549.17 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.22 mM), The compound is unstable in solution, please use soon. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
